Targeting a Moving Threshold: Antigen Density as a Design Constraint for Particulate Drug Delivery in HER2-Low and HER2-Ultralow Breast Cancer-A Narrative Review.
6 affiliations
- 1Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.
- 2Department of Obstetrics and Gynecology, Cuza Voda Hospital, 700038 Iasi, Romania.
- 3Department of Obstetrics and Gynecology, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
- 4Department of Obstetrics and Gynecology, Elias University Emergency Hospital, 050474 Bucharest, Romania.
- 5Department of Obstetrics, Gynecology and Human Reproduction, "Nicolae Testemițanu" State University of Medicine and Pharmacy, MD-2004 Chișinău, Moldova.
- 6Department of Obstetrics and Gynecology, Clinical Hospital of Obstetrics and Gynecology "Elena Doamna", 700038 Iasi, Romania.
Abstract
Trastuzumab deruxtecan has made breast tumours with minimal HER2 expression therapeutically actionable, and the descriptors HER2-low and HER2-ultralow now carry regulatory weight. Both were defined by immunohistochemical convention and trial eligibility rather than by calibrated measurement. For a receptor-directed particulate carrier the operative question is not whether HER2 is detectable, but whether enough surface-accessible receptor is present, and suitably distributed, to sustain multivalent attachment, clustering, internalisation and payload transfer. This narrative review asks whether principles established in HER2-overexpressing models, in non-HER2 receptor systems and on synthetic interfaces can defensibly be extrapolated to the HER2-low setting, keeping those evidence classes distinct. Antigen density acts at several stages of the delivery cascade rather than at binding alone, jointly with carrier design and tumour transport. An analytical constraint compounds this: fixed-tissue methods report tissue HER2 abundance but do not selectively quantify the accessible receptor pool a carrier can engage. Within the literature identified, no engagement threshold generalisable across platforms was found; the single measured value belongs to one liposomal system studied in vitro. Lesion-level carrier deposition varied widely in both human imaging datasets identified, which illustrate transport heterogeneity but are not comparable. Targetability is platform-specific, and should be measured rather than inferred from categorical HER2 status. No validated model links receptor abundance, ligand density, avidity and internalisation to biological response, so the framework offered is operational.
Related
- A dual-targeting lipid nanoparticle delivery system for precision phage therapy against multidrug-resistant Gram-negative bacteria
- Identification of B-cell maturation antigen (BCMA)-targeting peptides and selective drug delivery to multiple myeloma using peptide-targeted DM1 prodrug-loaded nanoparticles
- Particulate Matter Emissions from an Ammonia Spark-Ignition Engine
- Short-Rotation Coppice Pellets as Biofuels in a Modern Boiler with an Electrostatic Precipitator: Particulate Matter and Carbon Monoxide Emissions
- Redox Properties of the Copper Centers in Particulate Methane Monooxygenase
BibTeX
@article{sescu2026targeting,
title = {{Targeting a Moving Threshold: Antigen Density as a Design Constraint for Particulate Drug Delivery in HER2-Low and HER2-Ultralow Breast Cancer-A Narrative Review.}},
author = {Vasile Adrian Sescu and Alexandru Filipescu and Iustina Petra Solomon Condriuc and Mihaela Burac and Ioana Sadiye Scripcariu and Demetra Socolov and Răzvan Socolov and Alexandru Cărăuleanu},
journal = {Pharmaceutics},
year = {2026},
month = sep,
doi = {10.3390/pharmaceutics18101218},
url = {https://europepmc.org/article/MED/42942750},
note = {CC BY},
}
RIS
TY - JOUR
TI - Targeting a Moving Threshold: Antigen Density as a Design Constraint for Particulate Drug Delivery in HER2-Low and HER2-Ultralow Breast Cancer-A Narrative Review.
AU - Vasile Adrian Sescu
AU - Alexandru Filipescu
AU - Iustina Petra Solomon Condriuc
AU - Mihaela Burac
AU - Ioana Sadiye Scripcariu
AU - Demetra Socolov
AU - Răzvan Socolov
AU - Alexandru Cărăuleanu
PY - 2026
DA - 2026/09/25
JO - Pharmaceutics
DO - 10.3390/pharmaceutics18101218
UR - https://europepmc.org/article/MED/42942750
AB - Trastuzumab deruxtecan has made breast tumours with minimal HER2 expression therapeutically actionable, and the descriptors HER2-low and HER2-ultralow now carry regulatory weight. Both were defined by immunohistochemical convention and trial eligibility rather than by calibrated measurement. For a receptor-directed particulate carrier the operative question is not whether HER2 is detectable, but whether enough surface-accessible receptor is present, and suitably distributed, to sustain multivalent attachment, clustering, internalisation and payload transfer. This narrative review asks whether principles established in HER2-overexpressing models, in non-HER2 receptor systems and on synthetic interfaces can defensibly be extrapolated to the HER2-low setting, keeping those evidence classes distinct. Antigen density acts at several stages of the delivery cascade rather than at binding alone, jointly with carrier design and tumour transport. An analytical constraint compounds this: fixed-tissue methods report tissue HER2 abundance but do not selectively quantify the accessible receptor pool a carrier can engage. Within the literature identified, no engagement threshold generalisable across platforms was found; the single measured value belongs to one liposomal system studied in vitro. Lesion-level carrier deposition varied widely in both human imaging datasets identified, which illustrate transport heterogeneity but are not comparable. Targetability is platform-specific, and should be measured rather than inferred from categorical HER2 status. No validated model links receptor abundance, ligand density, avidity and internalisation to biological response, so the framework offered is operational.
SN - 1999-4923
ER -